Drug Insights

Is Somapacitan approved by the FDA?

5 July 2024
3 min read

Yes, somapacitan (Sogroya) is an FDA-approved growth hormone therapy for treating growth hormone deficiency in both adults and children over 2.5 years old. Approved on August 28, 2020, it offers a convenient once-weekly injection, improving adherence and quality of life for patients.

What is Somapacitan?

Somapacitan is a growth hormone used to treat growth hormone deficiency in both adults and children aged 2.5 years and older. It belongs to the drug class of growth hormones and is administered as a subcutaneous injection.

How Somapacitan Works

Somapacitan works by mimicking the effects of natural growth hormone in the body, which is crucial for growth, metabolism, and muscle development. It helps increase height in children and improve body composition, muscle mass, and overall energy levels in both children and adults with growth hormone deficiency.

Administration and Dosage

Somapacitan is administered as an injection under the skin (subcutaneous). The typical dosage is once a week, and the exact dose is determined by a healthcare provider based on the patient’s specific needs. Important administration guidelines include:

  • Your healthcare provider will show you how to inject somapacitan and rotate injection sites to avoid skin problems.
  • Do not reuse needles or syringes; dispose of them properly in a puncture-proof container.
  • Store the medication as instructed, usually at room temperature away from moisture and heat.

Potential Side Effects

Somapacitan can cause a range of side effects, from common to serious:

Common Side Effects:

  • Back and joint pain
  • Vomiting, heartburn
  • Dizziness
  • Weight gain
  • Sleep problems
  • Abnormal blood tests
  • Pain in hands and feet
  • Fever, chills, flu symptoms
  • Pain, bruising, or swelling at the injection site

Serious Side Effects:

  • Changes in behavior, moles, birthmarks, or skin color
  • Headaches, vision problems, nausea, or vomiting
  • Fluid retention causing shortness of breath, swelling, rapid weight gain
  • Decreased adrenal gland hormones leading to nausea, vomiting, loss of appetite
  • Pancreatitis with severe upper stomach pain spreading to the back

If you experience any serious side effects, you should contact your doctor immediately.

Warnings and Precautions

  • Allergies: Do not use if you are allergic to somapacitan.
  • Health Conditions: Inform your doctor if you have cancer, diabetes, adrenal or thyroid problems, or if you are a child with specific conditions like Prader-Willi syndrome.
  • Pregnancy and Breastfeeding: Consult your doctor if you are pregnant or breastfeeding.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Jul 5
Pharma Frontiers
10 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Jul 5
5 July 2024
Jul 5th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Is Clascoterone approved by the FDA?
Drug Insights
3 min read
Is Clascoterone approved by the FDA?
5 July 2024
Approved on August 26, 2020, clascoterone (Winlevi) offers a novel mechanism of action by inhibiting androgen receptors in the skin, reducing oil production and inflammation associated with acne.
Read →
Idorsia's JERAYGO: Europe's First and Only ERA Approved for Resistant Hypertension
Latest Hotspot
3 min read
Idorsia's JERAYGO: Europe's First and Only ERA Approved for Resistant Hypertension
5 July 2024
Idorsia’s JERAYGO (aprocitentan) approved in Europe as the first and only ERA for resistant hypertension treatment.
Read →
Is Oliceridine approved by the FDA?
Drug Insights
3 min read
Is Oliceridine approved by the FDA?
5 July 2024
Approved on August 7, 2020, oliceridine (Olinvyk) is intended for patients who have not found relief with other treatments.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.